TIANJIN DEV(00882): Tianjin Lisheng Pharmaceutical's net profit attributable to the parent company for the first three quarters was 371 million yuan, an increase of 119.05% year-on-year.

TIANJIN DEV (00882) announced that its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Tianjin Lisheng Pharmaceutical), has achieved a total operating income of 1.007 billion yuan in the nine months ending September 30, 2025, a decrease of 1.61% compared to the same period last year. Net profit attributable to the owners of the parent company was 371 million yuan, an increase of 119.05% year-on-year, with basic earnings per share of 1.44 yuan.